Literature DB >> 33477873

Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact.

David Højland Ipsen1, Pernille Tveden-Nyborg1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is becoming the leading chronic liver disease, negatively affecting the lives of millions of patients worldwide. The complex pathogenesis involves crosstalk between multiple cellular networks, but how the intricate communication between these cells drives disease progression remains to be further elucidated. Furthermore, the disease is not limited to the liver and includes the reprogramming of distant cell populations in different organs. Extracellular vesicles (EVs) have gained increased attention as mediators of cellular communication. EVs carry specific cargos that can act as disease-specific signals both locally and systemically. Focusing on NAFLD advancing to steatohepatitis (NASH), this review provides an update on current experimental and clinical findings of the potential role of EVs in hepatic inflammation and fibrosis, the main contributors to progressive NASH. Particular attention is placed on the characteristics of EV cargos and potential specificity to disease stages, with putative value as disease markers and treatment targets for future investigations.

Entities:  

Keywords:  extracellular vesicles; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Year:  2021        PMID: 33477873      PMCID: PMC7832840          DOI: 10.3390/biomedicines9010093

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  70 in total

1.  Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.

Authors:  Jinhang Gao; Bo Wei; Thiago M de Assuncao; Zhikui Liu; Xiao Hu; Samar Ibrahim; Shawna A Cooper; Sheng Cao; Vijay H Shah; Enis Kostallari
Journal:  J Hepatol       Date:  2020-05-08       Impact factor: 25.083

Review 2.  Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease.

Authors:  Adel Hammoutene; Pierre-Emmanuel Rautou
Journal:  J Hepatol       Date:  2019-02-21       Impact factor: 25.083

3.  Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.

Authors:  Kyle S McCommis; Wesley T Hodges; Elizabeth M Brunt; Ilke Nalbantoglu; William G McDonald; Christopher Holley; Hideji Fujiwara; Jean E Schaffer; Jerry R Colca; Brian N Finck
Journal:  Hepatology       Date:  2017-03-30       Impact factor: 17.425

4.  Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p.

Authors:  Li Chen; Ruju Chen; Victoria M Velazquez; David R Brigstock
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

5.  Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate.

Authors:  Hiroyuki Nojima; Christopher M Freeman; Rebecca M Schuster; Lukasz Japtok; Burkhard Kleuser; Michael J Edwards; Erich Gulbins; Alex B Lentsch
Journal:  J Hepatol       Date:  2015-08-05       Impact factor: 25.083

6.  Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression.

Authors:  Masashi Miyao; Hirokazu Kotani; Tokiko Ishida; Chihiro Kawai; Sho Manabe; Hitoshi Abiru; Keiji Tamaki
Journal:  Lab Invest       Date:  2015-07-27       Impact factor: 5.662

7.  Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.

Authors:  Petra Hirsova; Samar H Ibrahim; Anuradha Krishnan; Vikas K Verma; Steven F Bronk; Nathan W Werneburg; Michael R Charlton; Vijay H Shah; Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2016-01-05       Impact factor: 22.682

8.  Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.

Authors:  Christine C Hsu; Juliane S Troeger; Ingmar Mederacke; Peter Huebener; Xueru Mu; Dianne H Dapito; Jean-Philippe Pradere; Robert F Schwabe
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  The Immune Landscape in Nonalcoholic Steatohepatitis.

Authors:  Sowmya Narayanan; Fionna A Surette; Young S Hahn
Journal:  Immune Netw       Date:  2016-06-17       Impact factor: 6.303

Review 10.  Mitochondrial Dysfunction in the Transition from NASH to HCC.

Authors:  Mélissa Léveillé; Jennifer L Estall
Journal:  Metabolites       Date:  2019-10-16
View more
  6 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 2.  Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease.

Authors:  Ji Sun; Dianbao Zhang; Yiling Li
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

3.  Liver Steatosis is a Driving Factor of Inflammation.

Authors:  Raja Gopal Reddy Mooli; Sadeesh K Ramakrishnan
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-01-11

4.  Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.

Authors:  Qingfu Zhu; Hengrui Li; Zheng Ao; Hao Xu; Jiaxin Luo; Connor Kaurich; Rui Yang; Pei-Wu Zhu; Sui-Dan Chen; Xiao-Dong Wang; Liang-Jie Tang; Gang Li; Ou-Yang Huang; Ming-Hua Zheng; Hui-Ping Li; Fei Liu
Journal:  J Nanobiotechnology       Date:  2022-07-27       Impact factor: 9.429

Review 5.  Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?

Authors:  Alexandra Zisser; David H Ipsen; Pernille Tveden-Nyborg
Journal:  Biomedicines       Date:  2021-03-31

6.  NASH and Systemic Complications: From Basic to Clinical Research.

Authors:  Sabine Baumgartner; Ronit Shiri-Sverdlov
Journal:  Biomedicines       Date:  2021-12-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.